Abstract
Five-year survival in patients with unresectable non-small-cell lung cancer (NSCLC) is less than 10%. In the present phase II study, 43 patients with locally advanced stage IIIA or selected IIIB NSCLC were given four courses of carboplatin AUC = 6 and paclitaxel 200 mg/m2 (3-hour infusion), every 3 weeks. Responsive patients, when possible, underwent surgery followed by standard radiotherapy (50 Gy) or radiotherapy (60 Gy), with concurrent cisplatin as intravenous continuous infusion of 4 mg/m2/d. Sixteen of the 42 evaluable patients achieved partial response (38%) and 3 complete response (CR) (7%) for an overall response rate of 45% (95% CI 30.1-60.2). RO resectability rate was 29%, with 21% of pathologic CRs. Three more CRs were achieved with concurrent chemoradio-therapy in responsive but unresected patients. Grade III/IV hematologic toxicity was 9%, while one perioperative death occurred. The median duration of response was 14 months (range: 3-44+); median survival was 15 months (range: 9-47+). One-year and 2-year survival rates were 51% and 22%, respectively. The median survival in the responsive resected patients was 26 months, with 2-year survival of 57%. Carboplatin/paclitaxel represents an effective and well-tolerated induction therapy, suggesting its possible role in combination with radiotherapy as neoadjuvant treatment in locally advanced NSCLC in alternative to cisplatin-based regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 265-269 |
| Number of pages | 5 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 26 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2003 |
Fingerprint
Keywords
- Induction chemotherapy
- Multimodality treatment
- Non-small-cell lung cancer (SCLC)
- Radiation therapy
- Stage III
- Surgery
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC). / De Candis, Daniela; Stani, Simonetta Chiara; Bidoli, Paolo; Bedini, Vittorio Amedeo; Potepan, Paolo; Navarria, Pierina; Aglione, Stefania; Bajetta, Emilio.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 3, 06.2003, p. 265-269.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC)
AU - De Candis, Daniela
AU - Stani, Simonetta Chiara
AU - Bidoli, Paolo
AU - Bedini, Vittorio Amedeo
AU - Potepan, Paolo
AU - Navarria, Pierina
AU - Aglione, Stefania
AU - Bajetta, Emilio
PY - 2003/6
Y1 - 2003/6
N2 - Five-year survival in patients with unresectable non-small-cell lung cancer (NSCLC) is less than 10%. In the present phase II study, 43 patients with locally advanced stage IIIA or selected IIIB NSCLC were given four courses of carboplatin AUC = 6 and paclitaxel 200 mg/m2 (3-hour infusion), every 3 weeks. Responsive patients, when possible, underwent surgery followed by standard radiotherapy (50 Gy) or radiotherapy (60 Gy), with concurrent cisplatin as intravenous continuous infusion of 4 mg/m2/d. Sixteen of the 42 evaluable patients achieved partial response (38%) and 3 complete response (CR) (7%) for an overall response rate of 45% (95% CI 30.1-60.2). RO resectability rate was 29%, with 21% of pathologic CRs. Three more CRs were achieved with concurrent chemoradio-therapy in responsive but unresected patients. Grade III/IV hematologic toxicity was 9%, while one perioperative death occurred. The median duration of response was 14 months (range: 3-44+); median survival was 15 months (range: 9-47+). One-year and 2-year survival rates were 51% and 22%, respectively. The median survival in the responsive resected patients was 26 months, with 2-year survival of 57%. Carboplatin/paclitaxel represents an effective and well-tolerated induction therapy, suggesting its possible role in combination with radiotherapy as neoadjuvant treatment in locally advanced NSCLC in alternative to cisplatin-based regimens.
AB - Five-year survival in patients with unresectable non-small-cell lung cancer (NSCLC) is less than 10%. In the present phase II study, 43 patients with locally advanced stage IIIA or selected IIIB NSCLC were given four courses of carboplatin AUC = 6 and paclitaxel 200 mg/m2 (3-hour infusion), every 3 weeks. Responsive patients, when possible, underwent surgery followed by standard radiotherapy (50 Gy) or radiotherapy (60 Gy), with concurrent cisplatin as intravenous continuous infusion of 4 mg/m2/d. Sixteen of the 42 evaluable patients achieved partial response (38%) and 3 complete response (CR) (7%) for an overall response rate of 45% (95% CI 30.1-60.2). RO resectability rate was 29%, with 21% of pathologic CRs. Three more CRs were achieved with concurrent chemoradio-therapy in responsive but unresected patients. Grade III/IV hematologic toxicity was 9%, while one perioperative death occurred. The median duration of response was 14 months (range: 3-44+); median survival was 15 months (range: 9-47+). One-year and 2-year survival rates were 51% and 22%, respectively. The median survival in the responsive resected patients was 26 months, with 2-year survival of 57%. Carboplatin/paclitaxel represents an effective and well-tolerated induction therapy, suggesting its possible role in combination with radiotherapy as neoadjuvant treatment in locally advanced NSCLC in alternative to cisplatin-based regimens.
KW - Induction chemotherapy
KW - Multimodality treatment
KW - Non-small-cell lung cancer (SCLC)
KW - Radiation therapy
KW - Stage III
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=0038517767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038517767&partnerID=8YFLogxK
U2 - 10.1097/00000421-200306000-00012
DO - 10.1097/00000421-200306000-00012
M3 - Article
C2 - 12796598
AN - SCOPUS:0038517767
VL - 26
SP - 265
EP - 269
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 3
ER -